Prodrugs and drug-macromolecule conjugates having controlled drug release rates
The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.
1. A compound of the formula
wherein m is an integer of 1-10;
Z is a macromolecule;
L′ is a linker;
D is a drug or of a prodrug;
X is O or S;
A is alkenyl (C 2 ), aryl or absent;
each R 1 and R 2 is independently H; CN;
NO 2 ;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted alkenyl;
optionally substituted alkynyl; or
each R 1 and R 2 is independently COR 3 or SOR 3 or SO 2 R 3 wherein
R 3 is H or optionally substituted alkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted alkenyl;
optionally substituted alkynyl; or
OR or NR 2 wherein each R is independently H or optionally substituted alkyl; or
each R 1 and R 2 is independently SR 4 wherein
R 4 is optionally substituted alkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted alkenyl; or
optionally substituted alkynyl;
wherein R 1 and R 2 may be joined to form a 3-8 member ring; and
wherein both R 1 and R 2 cannot be H;
wherein R 5 is H or alkyl (C 1-6 ).
2. The compound of claim 1 wherein m is 1.
3. The compound of claim 1 wherein R 5 is H.
4. The compound of claim 1 wherein the linker residue is a bivalent chain having a molecular weight between 14 Da and 20 kDa which may include unsaturation, heteroatoms, ring structures, aromatic portions, and/or heteroaromatic portions that covalently links Z to the remainder of the molecule.
5. The compound of claim 4 wherein the linker is a peptide or a pseudopeptide and/or comprises triazole and/or phenylene, and/or a maleimido.
6. The compound of claim 1 wherein the macromolecule is an antibody, a polysaccharide, an albumin, or a synthetic polymer.
7. The compound of claim 6 wherein the synthetic polymer is polyethylene glycol (PEG).
8. The compound of claim 1 wherein the drug is a peptide, a nucleic acid or a small molecule.
9. The compound of claim 1 wherein one of R 1 and R 2 is CN.
10. The compound of claim 1 wherein at least of one R 1 and R 2 comprises phenyl or phenylene.
11. The compound of claim 1 wherein one of R 1 and R 2 is SO 2 R 3 and the other is H, alkyl or phenyl.
12. The compound of claim 1 wherein A is absent.
13. A compound of the formula
wherein m, R 1 , R 2 , R 5 , A, X and D are defined as in claim 1 , and wherein L is a linking group capable of binding to a macromolecule.
14. A compound of the formula
wherein R 1 , R 2 , R 5 , A, X, Z and L′ are defined as in claim 1 .
15. A pharmaceutical composition which comprises the compound of claim 1 .
16. A method to prepare a compound of formula (3) which method comprises reacting a compound of formula (2) with a macromolecule.
17. A method to prepare a compound of formula (3) which method comprises reacting a compound of formula (4) with a drug or prodrug under conditions whereby said drug or prodrug is coupled to the compound of formula (4).
18. A method to prepare a compound of formula (2) which method comprises reacting a compound of formula (1) with a drug or prodrug under conditions whereby said drug or prodrug is coupled to the compound of formula (1).